Under the agreement, Lilly scientists will have instant access to a private, collaborative, and secure analytical environment where they can use algorithms to process raw data for use in clinical studies or to create their own predictive models that can measure and understand a patient’s health by accessing consented data derived from smartphones, connected sensors, wearables, and voice.
The analysis will turn complex, patient-generated behavior data into quantifiable and clinically meaningful insights that can transform how diseases are identified, treated, and monitored, according to Lilly.
“By leveraging Evidation’s Andromeda platform, Lilly’s scientists are gaining a deeper understanding of the physiological, environmental, and contextual indicators that can help shape future advancements in medicine and medicine delivery,” said Divakar Ramakrishnan, Lilly’s chief digital officer.
Evidation’s data platform already is being used by Lilly to analyze data from continuous glucose monitors, insulin pumps, and real world information for diabetes patients to support efforts aimed at building a connected ecosystem that includes an automated insulin delivery device and connected insulin pen.
Terms of the agreement are not disclosed.
Founded in 2012, Evidation Health is headquartered in San Mateo, California and maintains additional offices in San Francisco and Santa Barbara.
(Source: Eli Lilly and Company)